SDUY127 

SDUY127 is a bivalent SHP2 inhibitor with an IC₅₀ value of 16 nM. SDUY127 binds simultaneously to the tunnel allosteric site and latch allosteric site of SHP2 at a 1:1 stoichiometric ratio, stabilizes the protein in an inactive conformation, and induces sustained inhibition of the MAPK signaling pathway. SDUY127 can be used in research related to leukemia and hepatocellular carcinoma^[1].

SDUY127 (1-3 μM; 48 h) inhibits MV4-11 leukemia cell proliferation by 33% at 1 μM and 79% at 3 μM after 48 h of treatment^[1].
SDUY127 (10-30 μM; 48 h) inhibits Hep3B hepatocellular carcinoma cell proliferation by 23% at 10 μM and 84% at 30 μM after 48 h of treatment^[1].
SDUY127 (3 μM; 15 min; 2 h) induces sustained suppression of ERK phosphorylation in MV4-11 cells, maintaining ~76% inhibition at 2 h post-treatment^[1].
SDUY127 (3 μM; 15 min; 2 h) induces transient suppression of ERK phosphorylation in Hep3B cells, with inhibition decreasing from ~76% at 15 min to ~48% at 2 h post-treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1195.22

C₅₈H₆₉Cl₂N₁₃O₉S

COC1=C(C=CC=C1C(N2C3=C4C=CC=C3)=NN=C2N(C4=O)CC5=CC=CC=C5Cl)OCCOCCOCCOCCN6CCN(CC6)C(CCCNC(CC(NC7=CC=CC(SC8=C(N)N=C(N9CCC(C)(CC9)N)C=N8)=C7Cl)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhu C, et al. Dual Allosteric Targeting of SHP2: Development of Bivalent Inhibitors with Enhanced Potency for Cancer Treatment. J Med Chem. 2026;69(10):11819-11843.